drugset / Trial / NCT07015398
A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the effect of steady-state NAL ER on the pharmacokinetics (PK) of pirfenidone or nintedanib and the effect of steady-state pirfenidone or nintedanib on the PK of NAL ER in healthy participants.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2025-09-12
- Completion
- 2025-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nalbuphine | Small molecule | — | Oral |
| Subject | Nintedanib | Small molecule | — | Oral |
| Subject | Pirfenidone | Small molecule | — | Oral |
Indications
No indication recorded.